PF-Atlas › Clinical Trials › NCT04645368
Study of Longidaze in the Prevention & Treatment of Pulmonary Fibrosis, Interstitial Lung Diseases Caused by COVID-19
bovhyaluronidase azoxymer · Not specified
Registry ID
NCT04645368
Phase
Not specified
Status
Completed
Drug / intervention
bovhyaluronidase azoxymer
Sponsor
NPO Petrovax
Start
2020-07-01
Enrollment
160
Locations
15
About this trial
A study is being conducted to evaluate the efficacy and safety of Longidaze for the prevention and treatment of post-inflammatory pulmonary fibrosis and interstitial lung disease following COVID-19.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT04645368 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.